Inactive Instrument

Analyst Reco. Epizyme, Inc.

Equities

EPZM

US29428V1044

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cowen Downgrades Epizyme to Market Perform From Outperform; Price Target is $1.50	22-06-28	MT
Wedbush Cuts Epizyme to Neutral From Outperform, Price Target to $1.45 From $7, Citing Ipsen Offer	22-06-27	MT
HC Wainwright Adjusts Epizyme's Price Target to $6 From $8, Reiterates Buy Rating	22-06-03	MT
HC Wainwright Adjusts Epizyme Price Target to $8 From $10, Maintains Buy Rating	22-05-12	MT
Wedbush Adjusts Price Target for Epizyme to $7 From $9, Maintains Outperform Rating	22-05-10	MT
HC Wainwright Adjusts Epizyme's Price Target to $10 from $15, Keeps Buy Rating	22-03-02	MT
Wedbush Trims Price Target for Epizyme to $9 From $12, Maintains Outperform Rating	22-03-02	MT
EPIZYME : Morgan Stanley Lowers Epizyme to Underweight From Equal-Weight, Price Target to $5 From $10	21-08-10	MT
EPIZYME : HC Wainwright Adjusts Epizyme's Price Target to $15 From $36, Maintains Buy Rating	21-08-10	MT
EPIZYME : Wedbush Cuts Epizyme's Price Target to $12 From $26, Citing 'Lower-Than-Expected' Tazverik Sales; Outperform Rating Kept	21-08-10	MT
EPIZYME : Morgan Stanley Adjusts Epizyme's Price Target to $10 From $11, Keeps Equal-Weight Rating	21-05-07	MT
EPIZYME : SVB Leerink Upgrades Epizyme to Outperform From Market Perform, Adjusts Price Target to $16 From $12	21-05-07	MT
EPIZYME : Wedbush Adjusts Epizyme's Price Target to $26 From $27, Maintains Outperform Rating	21-05-06	MT
EPIZYME : Morgan Stanley Adjusts Price Target on Epizyme to $11 From $14, Maintains Equal-Weight Rating	21-04-19	MT
EPIZYME : Credit Suisse Starts Epizyme at Outperform with $13 Price Target	21-03-31	MT
EPIZYME : Morgan Stanley Downgrades Epizyme to Equal-Weight From Overweight; Price Target is $14	21-02-25	MT
EPIZYME : Jefferies Downgrades Epizyme to Hold From Buy, Adjusts Price Target to $14 From $18	20-12-21	MT
EPIZYME : Barclays Adjusts Epizyme's Price Target to $18 From $33, Maintains Overweight Rating	20-11-09	MT
EPIZYME : Morgan Stanley Adjusts Epizyme PT to $27 From $29, Maintains Overweight Rating	20-11-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer